The impact of changing antimuscarinics on quality of live in patients with overactive bladder - results of the VEST trial
Abstract
Primary Objective: The authors present the results of a multicentre, noninterventional, prospective, one-arm, observational study into the effect of solifenacin on the quality of life versus previous antimuscarinic treatment. Method: Satisfaction with treatment was measured by erception of Treatment Satisfaction (TSVAS), Over Active Bladder-q Short Form (OAB-q SF) and EuroQol Group scoring system (EQ-5D-5L) Results: A representative sample of the OAB population was evaluated in the study (2000 patients included in 60 centers in the Czech Republic, 1481 patients completed all 5 evaluations and 1,892 patients had baseline and at least 1 post-treatment).
Improvements in QoL and OAB symptoms were observed over a period of 12 months in the population of patients treated with solifenacin 5-10 mg and previously treated with other antimuscarinic agents. OAB-q SF scores, including Total HRQoL Score, all HRQoL subscores and Symptom Severity Score, all improved over the study period.
Changes in TS-VAS scores also demonstrated improvements in overall QoL over the study period. The EQ-5D-5L showed shifts towards improved QoL for all dimensions.
Data from 3-day bladder diaries demonstrated improvements in OAB symptoms over the course of the study, including frequency, urgency, nocturia and incontinence. Solifenacin was well tolerated in the current study with only 15 non-serious, mild adverse events reported, mainly dry mouth (n=12).
Solifenacin did not have any notable effect on post-void residual volume, risk of urinary retention or any effect on urinary flow rate. Conclusion: The study shows statistical improvements in all parameters evaluated.
According to the results, solifenacin is a suitable drug for patients who fail treatment with other antimuscarinics.